Welcome to our dedicated page for Proassurance Cp SEC filings (Ticker: PRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ProAssurance Corporation filings document the formal disclosures of a property and casualty insurance holding company. The company's reports cover professional liability insurance for healthcare providers and attorneys, workers' compensation insurance, reinsurance-related activity, corporate costs, and investment portfolio information.
Its SEC filings include Form 8-K material-event reports, operating and financial results, Regulation FD investment portfolio updates, capital-structure disclosures, governance matters, material agreements, shareholder voting matters, risk factors, and executive compensation arrangements. These filings also provide the regulatory record for segment performance and corporate actions affecting the company's public-company structure.
ProAssurance Corporation (NYSE: PRA) reported that shareholders overwhelmingly approved all proposals connected with its pending merger with The Doctors Company at a special meeting held on 24 June 2025.
• Merger Agreement adoption: 38,225,337 shares voted FOR, just 363,050 AGAINST and 22,192 ABSTAIN; no broker non-votes were recorded. Support exceeded 99% of votes cast, comfortably surpassing any approval threshold.
• Say-on-Pay (merger-related compensation): 31,191,544 FOR, 7,185,578 AGAINST, 233,457 ABSTAIN—an 81% approval rate on an advisory basis.
• Adjournment proposal: Not required because quorum (≈75.6% of outstanding 51,070,243 shares) was achieved and the merger proposal passed.
Under the Agreement and Plan of Merger signed 19 March 2025, Jackson Acquisition Corporation (a wholly owned subsidiary of The Doctors Company) will merge with and into ProAssurance, making ProAssurance a wholly owned subsidiary of The Doctors Company. Management currently expects closing in the first half of 2026, subject to regulatory clearances and other customary conditions.
The filing reiterates extensive forward-looking risk factors, including regulatory approvals, potential litigation, business disruption, personnel retention and market reactions during the pre-closing period. A related news release (Exhibit 99.1) announcing the vote results was issued the same day.